Stock data
Spero Therapeutics, Inc. (SPRO)
Spero Therapeutics, Inc. (SPRO) reported revenue of US$12.59M and net income of US$8.57M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$12.59M | — | US$6.31M | US$8.57M | — |
| 2024 | US$0.37M | — | -US$73.36M | -US$68.57M | — |
| 2023 | US$0.93M | — | US$21.48M | US$22.81M | — |
| 2022 | US$2.50M | — | -US$42.20M | -US$46.41M | — |
| 2021 | US$3.07M | — | -US$87.97M | -US$89.80M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$0.00M | -US$9.55M | — |
| 2026-03-31 | US$0.00M | -US$7.20M | — |
| 2025-12-31 | US$12.57M | US$31.52M | — |
| 2025-09-30 | US$0.00M | -US$7.38M | — |
| 2025-06-30 | US$0.00M | -US$1.70M | — |
| 2025-03-31 | US$0.01M | -US$13.87M | — |
| 2024-12-31 | US$0.05M | -US$20.89M | — |
| 2024-09-30 | US$0.07M | -US$17.15M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.